A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma

• DOI: 10.1016/j.tranon.2021.101084
• Publication Date: 2021-03-28T15:36:19Z
• Authors: Soledad Iseas; Mariano Golubicki; Juan Robbio; Gonzalo Ruiz; Florencia Guerra; Javier Mariani; Ruben Salanova; Ana Cabanne; Martin Eleta; Joaquin V. Gonzalez; Jorge Basiletti; María Alejandra P...; Guillermo Mascian...; Marcela Carballido; Enrique Roca; Guillermo Mendez; Mariana Coraglio; Martin C. Abba
• Keywords: Chemoradiotherapy

Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal malignancy associated with high-risk Human papillomavirus (HPV) infection. Despite improved outcomes in non-metastatic ASCC, definitive chemoradiotherapy constitutes the standard treatment for localized disease. Evidences predictive and prognostic biomarkers are limited. Here, we performed viral, immune, mutational characterization of 79 ASCC patients complete chemoradiotherapy. HPV-16 was detected 91% positive cases single infections (78%) or coinfections multiple genotypes (22%). Fifty-four percent displayed mutations affecting cancer driver genes such as PIK3CA (21% cases), TP53 (15%), FBXW7 (9%), APC (6%). PD-L1 expression 57% ASCC. Increased (67%) were response compared non-complete to (37%) (p = 0.021). Furthermore, tumors significantly better disease-free survival (DFS) overall (OS) negative 0.006 p 0.002, respectively). strongly impacts CR rate after could be used stratify good versus poor responders avoiding morbidity abdominal perineal resection.